Oncology Test Portfolio

OncoGxSelect OncoGxSelect™

OncoGxSelect™ analyzes a patient’s tumor for genetic mutations frequently found in select cancers. This test utilizes Next Generation Sequencing (NGS) technology to detect alterations in 12 known oncogenes and is aligned with well-established molecular testing guidelines. Actionable results help guide therapeutic decisions related to targeted cancer therapy. Additionally, OncoGxSelect™ detects all types of mutations (SNV, gene fusion, Indel, CNV) with a high degree of accuracy.

View OncoGxOne™ Comprehensive Panel

Target Oncogenes

ALKBRAFEGFRERBB2KITKRAS
MAP2K1METNRASPIK3CARETROS1

Types of Alterations Detected

SNVs1 OncoGxSelect™

SNVs

Fusions OncoGxSelect™

Fusions

CNVS2 OncoGxSelect™

CNVs

Indels OncoGxSelect™

Indels

Relevant Solid Tumor Types

GeneVariantTypeResponsiveResistant
ALKEML4-ALKFusionCrizotinib, Ceritinib, AlectinibGefitinib, Erlotinib, Afatinib
KIF5B-ALK
TFG-ALK
T1151_L1152insTIndel Crizotinib
L1152RSNV 
C1156Y 
F1174L 
L1196MBrigatinib
G1202R
S1206Y 
G1269A 
BRAFV600ESNVVemurafenib, Dabrafenib, Dabrafenib+Trametinib 
ERBB2A775_G776insYVMAIndelTrastuzumab, Afatinib 
G776_777insVC 
Exon20_ins 
G776LSNVTrastuzumab 
EGFRG719ASNVGefitinib, Erlotinib 
G719C 
G719S 
D761Y Gefitinib, Erlotinib
K745_A750delIndelGefitinib, Erlotinib, Afatinib 
E746_A750del 
E746_A750delELREA 
E746_S752delinsA 
L747_S752del 
Exon19_del 
A763_Y764insFQEA 
D770_N771insSVD Gefitinib, Erlotinib
Exon20_ins 
T790MSNVOsimertinib
C797S Osimertinib
L858RGefitinib, Erlotinib, Afatinib 
L861QGefitinib, Erlotinib 
KRASG12ASNV Gefitinib, Erlotinib
G12C 
G12D 
G12R 
G12S 
G12V 
G13A 
G13C 
G13D 
G13R 
G13S 
G13V 
Q61H 
Q61K 
Q61L 
Q61R 
METAmplificationCNVCrizotinib 
Exon14_skippingFusion 
RETNCOA4-RETFusionCabozantinib 
CCDC6-RET 
KIF5B-RET 
ROS1CD74-ROS1FusionCrizotinib 
GOPC-ROS1 
SLC34A2-ROS1 
EZR-ROS1 
SDC4-ROS1 
TPM3-ROS1 
LRIG3-ROS1 
GeneVariantTypeResponsiveResistant
BRAFV600ESNVDabrafenib+Trametinib, Vemurafenib+Cobimetinib
V600KDabrafenib+Trametinib, Vemurafenib+Cobimetinib, Vemurafenib, Dabrafenib
KITAmplificationCNVImatinib
W557RSNV
V559A
V560D
L576P
K642E
MAP2K1C121SSNVTrametinib
GeneVariantTypeResponsiveResistant
ALKSTRN-ALKFusionCrizotinib, Ceritinib
EML4-ALK
BRAFV600ESNVVemurafenib, Dabrafenib
EGFRAmplificationCNVVandetanib
METAmplificationCNVCabozantinib
RETNCOA4-RETFusionVandetanib, Cabozantinib
CCDC6-RET
C634WSNVVandetanib
C634R
C634Y
M918T
GeneVariantTypeResponsiveResistant
N/AWTCetuximab, Panitumumab
BRAFV600ESNVCetuximab, Panitumumab
KRASG12ASNVCetuximab, Panitumumab
G12C
G12D
G12R
G12S
G12V
G13A
G13C
G13D
G13R
G13S
G13V
Q61H
Q61K
Q61L
Q61R
K117N
A146P
A146T
A146V
NRASG12ASNVCetuximab, Panitumumab
G12C
G12D
G12R
G12S
G12V
G13A
G13C
G13D
G13R
G13S
G13V
Q61H
Q61K
Q61L
Q61R
GeneVariantTypeResponsiveResistant
ERBB2AmplificationCNVTrastuzumab,  Trastuzumab+Chemotherapy
EGFROverexpressionNimotuzumab
KITWTRegorafenibImatinib
L576PSNVImatinib
W557R
V559A
K642E
V560delIndel
PDGFRAD842VSNVDasatinibImatinib
GeneVariantTypeResponsiveResistant
ERBB2AmplificationCNVTrastuzumab,  Trastuzumab+Chemotherapy
PIK3CAH1047RSNVTemsirolimus, Everolimus

OncoGxSelect™ Report 

OncoGxOne__Plus_Sample_report_thumb OncoGxSelect™

OncoGxSelect™ Information Sheet 

OncoGxSelect_Info_sheet_thumb-1 OncoGxSelect™